India Pharmacists Ban Sales Of Combo Drugs With Safety Issues (India)
This article was originally published in PharmAsia News
Despite a court stay against a proposed government ban on combination drugs, most of India's retail pharmacists plan to refuse to sell them. The All India Organization of Chemists and Druggists, which represents two-thirds of pharmacists in India, said it was following a directive of the regulatory authority to withdraw licenses of combination drugs that failed to comply with quality standards. The drugs, which account for more than 10 percent of retail pharmacy drug sales in the country, had been approved without having undergone proper quality-safety tests. Regulators count 186 new applications for the combinations that involve combining two or more already-approved drugs into a single formulation, and 50 of them have been rejected so far because of inadequate proof of quality and efficacy. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.